CAESAREA, Israel, May 20, 2024
/PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or
the "Company"), developer of the ProSense® System, a
minimally-invasive cryoablation technology that destroys tumors by
freezing as an alternative to surgical tumor removal, today
announced the Company's CEO, Eyal
Shamir, will present via a fireside chat at the A.G.P /
Alliance Global Partners' Virtual Healthcare Company Showcase on
Tuesday, May 21, 2024, at
8:20am EDT. Investors may register to
view the presentation at the virtual conference through the
following LINK.
Mr. Shamir will present an update on the latest developments and
catalysts for IceCure, including the recently announced results of
the ICE3 breast cancer cryoablation trial, its pending De Novo
Classification Request with the U.S. Food and Drug Administration
("FDA") for marketing clearance of the ProSense® Cryoablation
System for the treatment of patients with early-stage, low risk
breast cancer, as well as ProSense®'s increasing global commercial
reach and growing body of independent research on the efficacy and
safety of ProSense in women's health and interventional
oncology.
"This has already been an incredibly productive year for IceCure
Medical as we completed the ICE3 study, published positive top line
results and submitted the complete dataset to the FDA last month,"
commented Eyal Shamir, Chief
Executive Officer. "These are exciting developments, and the
conference allows us to highlight our achievements and share our
vision for the next phase upon a successful outcome with the FDA
and enhance shareholder value as we accelerate our commercial goals
for ProSense in the U.S. market."
About ProSense®
The ProSense® Cryoablation System provides a minimally invasive
treatment option to destroy tumors by freezing them. The system
uniquely harnesses the power of liquid nitrogen to create large
lethal zones for maximum efficacy in tumor destruction in benign
and cancerous lesions, including breast, kidney, lung, and
liver.
ProSense® enhances patient and provider value by accelerating
recovery, reducing pain, surgical risks, and complications. With
its easy, transportable design and liquid nitrogen utilization,
ProSense® opens that door to fast and convenient office-based
procedure for breast tumors.
About IceCure Medical
IceCure Medical (Nasdaq: ICCM) develops and markets ProSense®,
an advanced liquid-nitrogen-based cryoablation therapy for the
treatment of tumors (benign and cancerous) by freezing, with the
primary focus areas being breast, kidney, bone and lung cancer. Its
minimally invasive technology is a safe and effective alternative
to hospital surgical tumor removal that is easily performed in a
relatively short procedure. The system is marketed and sold
worldwide for the indications cleared and approved to date
including in the U.S., Europe, and
China.
IR Contact:
Email: investors@icecure-medical.com
Michael Polyviou
Phone: 732-232-6914
Todd Kehrli
Phone: 310-625-4462
Logo:
https://mma.prnewswire.com/media/2319310/IceCure_Medical_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/icecure-medical-to-highlight-key-achievements-and-provide-business-overview-at-agp--alliance-global-partners-virtual-healthcare-company-showcase-302149964.html
SOURCE IceCure Medical